Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-2496
Strasser, F; Lutz, T A; Maeder, M T; Thuerlimann, B; Bueche, D; Tschöp, M; Kaufmann, K; Holst, B; Brändle, M; von Moos, R; Demmer, R; Cerny, T (2008). Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer, 98:300-308.
View at publisher
Twenty-one adult patients were randomized to receive ghrelin on days 1 and 8 and placebo on days 4 and 11, or vice versa, given intravenously over a 60– minute period before lunch: 10 received 2µg/kg (lower-dose) ghrelin; 11 received 8µg/kg (upper-dose) ghrelin. Active and total ghrelin, growth-hormone, and IGF-1 levels were monitored at baseline (4-5 days before day 1), during treatment days, and at end-of-study (day 17/18). Drug-related adverse events (assessed by NCI-CTC-toxicity criteria and cardiac examination), did not differ between ghrelin and placebo. No grade 3/4 toxicity or stimulation of tumor growth was observed. The peak increase of growth-hormone, a biological marker of ghrelin action, was 25ng/ml with lower-dose and 42ng/ml with upperdose ghrelin. Morning fasting total ghrelin levels were higher (p<0.05) for upperdose patients at end-of-study (3580pg/ml) than at baseline (990pg/ml). IGF-1 levels did not change. At day 8, 81% of patients preferred ghrelin over placebo and at the end-of-study, 63%. Nutritional intake and eating-related symptoms, measured to explore preliminary efficacy, did not differ between ghrelin and placebo. Ghrelin is well tolerated and safe in patients with advanced cancer. For safety, tolerance, and patients’ preference for treatment no difference was observed between the lower and upper-dose group.
145 downloads since deposited on 16 May 2008
34 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||05 Vetsuisse Faculty > Institute of Veterinary Physiology
04 Faculty of Medicine > Center for Integrative Human Physiology
|Dewey Decimal Classification:||570 Life sciences; biology
610 Medicine & health
|Deposited On:||16 May 2008 15:19|
|Last Modified:||05 Apr 2016 12:23|
|Publisher:||Nature Publishing Group|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page